Initiating allopurinol therapy: do we need to know the patient's human leucocyte antigen status?
about
2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemiaHLA associations and clinical implications in T-cell mediated drug hypersensitivity reactions: an updated review.PharmGKB summary: very important pharmacogene information for human leukocyte antigen B.HLA-B (*) 58:01 for Allopurinol-Induced Cutaneous Adverse Drug Reactions: Implication for Clinical Interpretation in Thailand.Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview.Understanding the dose-response relationship of allopurinol: predicting the optimal dosage.Approach to the diagnosis of drug hypersensitivity reactions: similarities and differences between Europe and North America.HLA and pharmacogenetics of drug hypersensitivity.Latest advances in predicting DILI in human subjects: focus on biomarkers.Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012.HLA-B*5801: utility and cost-effectiveness in the Asia-Pacific Region.PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics.Role of dermatology in pharmacogenomics: drug-induced skin injury.Genetic markers associated with cutaneous adverse drug reactions to allopurinol: a systematic review.Allopurinol hypersensitivity: investigating the cause and minimizing the risk.Diagnostic utility of HLA-B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta-analysis.Stevens-Johnson syndrome and toxic epidermal necrolysis: an update on pharmacogenetics studies in drug-induced severe skin reaction.HLA Association with Drug-Induced Adverse Reactions.HLA-B*58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis in a Portuguese population.
P2860
Q24612292-FB5DC234-B457-4129-80B5-610CA61ED16EQ33666857-494CAB98-742F-48A7-81D2-A6C47336AAF2Q35168561-6073C557-09ED-4EA2-972C-C40B2E00663AQ37100410-D6A63065-B526-4443-AD7A-47B60AD1CDB2Q37127097-B71A61DA-42CF-4478-BF41-923253B64F5BQ37353448-E7E214CE-5D36-460E-B2F9-AEA9A5024D59Q37695437-20286624-7413-4C86-A044-3EFB88366B8FQ38037649-3590F8D3-E6C7-41D8-9754-096A45CAEF99Q38045377-3D2125A6-5C63-49FB-835D-4AB21391D66AQ38123116-A29D4AB1-22EA-4619-B57F-F45B5CC602ACQ38131961-507E1EDE-438D-4B6C-B0BD-23E67087292BQ38219092-F1B71286-DEE0-4ED8-8D36-D3E051BEF2B3Q38396234-390189C5-BDA9-4B6B-AE32-F266DBDCC01AQ38474868-02F51531-ACD6-4C23-AAB3-907E31AF551CQ38594891-FA0554D6-AC6E-4A57-BF2D-10415CB572C9Q38600529-0E86CCB1-5B88-482C-AC4C-1AC5D47ADC0FQ38629821-B3F0F35B-4580-4989-A341-2C3969E32B9FQ47553722-2A91EBA4-218E-4FA2-87C3-93B6D374912BQ51060800-18AB6BF1-A125-4E51-A1EE-B8DA3E188448
P2860
Initiating allopurinol therapy: do we need to know the patient's human leucocyte antigen status?
description
im April 2012 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 April 2012
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована у квітні 2012
@uk
name
Initiating allopurinol therapy ...... uman leucocyte antigen status?
@en
Initiating allopurinol therapy ...... uman leucocyte antigen status?
@nl
type
label
Initiating allopurinol therapy ...... uman leucocyte antigen status?
@en
Initiating allopurinol therapy ...... uman leucocyte antigen status?
@nl
prefLabel
Initiating allopurinol therapy ...... uman leucocyte antigen status?
@en
Initiating allopurinol therapy ...... uman leucocyte antigen status?
@nl
P2093
P2860
P1476
Initiating allopurinol therapy ...... uman leucocyte antigen status?
@en
P2093
E J Phillips
G G Graham
J Anderson
J R Sullivan
K M Williams
S L Stocker
P2860
P304
P356
10.1111/J.1445-5994.2011.02567.X
P50
P577
2012-04-01T00:00:00Z